Version 1
: Received: 2 May 2022 / Approved: 13 May 2022 / Online: 13 May 2022 (15:14:42 CEST)
How to cite:
Roncoletta, M.; Morani, E.D.S.C.; De Salles, N.A.A.; Ferraz, G.C. In Vitro Bovine Embryo Production Using Medium’s Supplemented with Recombinant Human Galectin-1 Buffered. Preprints2022, 2022050193. https://doi.org/10.20944/preprints202205.0193.v1.
Roncoletta, M.; Morani, E.D.S.C.; De Salles, N.A.A.; Ferraz, G.C. In Vitro Bovine Embryo Production Using Medium’s Supplemented with Recombinant Human Galectin-1 Buffered. Preprints 2022, 2022050193. https://doi.org/10.20944/preprints202205.0193.v1.
Cite as:
Roncoletta, M.; Morani, E.D.S.C.; De Salles, N.A.A.; Ferraz, G.C. In Vitro Bovine Embryo Production Using Medium’s Supplemented with Recombinant Human Galectin-1 Buffered. Preprints2022, 2022050193. https://doi.org/10.20944/preprints202205.0193.v1.
Roncoletta, M.; Morani, E.D.S.C.; De Salles, N.A.A.; Ferraz, G.C. In Vitro Bovine Embryo Production Using Medium’s Supplemented with Recombinant Human Galectin-1 Buffered. Preprints 2022, 2022050193. https://doi.org/10.20944/preprints202205.0193.v1.
Abstract
As recommended in the ICH Guidelines (S5-R2 and S6-R1), and based on bioethical concerns, we chose bovine embryos (BE) to check the in vitro embryo development considering the use of different amounts of rHGAL-1 as supplementations of in vitro embryo culture (IVP) mediums. Based on procedures for commercial BE in vitro production, using oocytes aspirated from slaughterhouse ovaries, the rHGAL-1 supplementation performed in two experiments (#01 on the oocyte maturation - IVM medium supplemented and experiment #2 on culture step IVC, supplemented SOF medium). There were IVP commercial procedures done, with 3 IVP batches per experiment and distributed the oocytes in four groups of treatment (one control group and three different dosages of rHGAL-1 to supplement both IVM and SOF mediums, using (2, 20 and 40µg.mL-1 respectively). A total of 962 (experiment 1) and 1,213 (experiment 2) oocytes were aspirated and submitted to IVP procedure. There was no damage to in vitro bovine embryos growth, considering cleavage percentage (%CLE), blastocysts development on day 7 (BlD7, BxD7, BhD7), or hatching blastocysts maturation on day 8 (BhD8%), regardless of rHGAL-1 supplementation. The immunohistochemistry assay with D8 embryos cultivated with rHGAL-1 supplementation on the culture medium (SOF medium) could demonstrate the presence of exogenous GAL-1, distributed in mass cell and trophoblastic cells, and the profile observed is dependent of exogenous supplementation and it was more evident in hatched embryos. The findings reassure the use of a reasonable amount of rHGAL-1 for in vitro embryonic development and make using rHGAL-1 in assisted reproduction in humans more reliable and safer.
MEDICINE & PHARMACOLOGY, Pharmacology & Toxicology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
.jpeg)
,
,
,
